Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
The Lancet HIV
DOI
Abstract
Young children living with HIV have few treatment options. We aimed to assess the efficacy and safety of dolutegravir-based antiretroviral therapy (ART) in children weighing between 3 kg and less than 14 kg.
Description
Keywords
Citation
Amuge, P., Lugemwa, A., Wynne, B., Mujuru, H. A., Violari, A., Kityo, C. M., ... & Goodman, A. (2022). Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. The Lancet HIV, 9(9), e638-e648.